The Europe Artificial Intelligence (AI) in drug discovery market was valued at USD 916.45 million in 2025 and is projected to reach USD 26,113.04 million by 2033, growing at a CAGR of 52.0% from 2026 to 2033. The market is witnessing robust growth driven by increasing adoption of AI-powered platforms in pharmaceutical research, rising investments in biotechnology innovation, and growing demand for faster and more cost-efficient drug development processes.
The rising burden of chronic diseases, cancer, and rare disorders across Europe, coupled with the need to reduce drug discovery timelines and clinical development costs, is encouraging pharmaceutical companies, biotechnology firms, and research institutions to integrate advanced AI technologies into their R&D workflows. Machine learning, deep learning, and generative AI solutions are increasingly being utilized for target identification, molecule design, lead optimization, and predictive analytics, enabling researchers to improve success rates and accelerate the development of novel therapeutics.